Jagsonpal Pharmaceuticals Limited Total Liabilities
Jagsonpal Pharmaceuticals Limited total liabilities. Based on the latest financial reports, Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) has total liabilities worth Rs-2.76 Billion INR (≈ $-29.87 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check JAGSNPHARM asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Jagsonpal Pharmaceuticals Limited (2006–2026)
Total liabilities of Jagsonpal Pharmaceuticals Limited from 2006 to 2026. This chart illustrates how Jagsonpal Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Jagsonpal Pharmaceuticals Limited to see how much of total assets are deployed in long-term investments.
Jagsonpal Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of Jagsonpal Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Evolution Petroleum Corporation Inc
NYSE MKT:EPM
|
USA | $101.72 Million |
|
CareRx Corp
TO:CRRX
|
Canada | CA$133.56 Million |
|
Meeka Metals Ltd
AU:MEK
|
Australia | AU$43.12 Million |
|
Thirumalai Chemicals Limited
NSE:TIRUMALCHM
|
India | Rs28.12 Billion |
|
CCS Supply Chain Management Co Ltd
SHG:600180
|
China | CN¥15.16 Billion |
|
Sapura Energy Bhd
KLSE:5218
|
Malaysia | RM7.69 Billion |
|
Nextronics Engineering
TWO:8147
|
Taiwan | NT$1.26 Billion |
|
Doosan Co Ltd
KO:000157
|
Korea | ₩20.11 Trillion |
Liability Composition Analysis (2006–2026)
This chart breaks down Jagsonpal Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Jagsonpal Pharmaceuticals Limited balance sheet assets.
Liquidity & Leverage Metrics
Jagsonpal Pharmaceuticals Limited Total Liabilities Ratios Explained
Jagsonpal Pharmaceuticals Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | N/A | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jagsonpal Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jagsonpal Pharmaceuticals Limited (2006–2026)
The table below shows the annual total liabilities of Jagsonpal Pharmaceuticals Limited from 2006 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs405.05 Million ≈ $4.38 Million |
+5.73% |
| 2025-03-31 | Rs383.10 Million ≈ $4.14 Million |
+29.09% |
| 2024-03-31 | Rs296.76 Million ≈ $3.21 Million |
-17.70% |
| 2023-03-31 | Rs360.56 Million ≈ $3.90 Million |
-4.10% |
| 2022-03-31 | Rs375.99 Million ≈ $4.07 Million |
-11.06% |
| 2021-03-31 | Rs422.73 Million ≈ $4.57 Million |
+17.68% |
| 2020-03-31 | Rs359.21 Million ≈ $3.88 Million |
+14.72% |
| 2019-03-31 | Rs313.11 Million ≈ $3.39 Million |
-1.44% |
| 2018-03-31 | Rs317.68 Million ≈ $3.44 Million |
-2.84% |
| 2017-03-31 | Rs326.97 Million ≈ $3.54 Million |
-46.32% |
| 2016-03-31 | Rs609.17 Million ≈ $6.59 Million |
+3.61% |
| 2015-03-31 | Rs587.94 Million ≈ $6.36 Million |
+1.95% |
| 2014-03-31 | Rs576.68 Million ≈ $6.24 Million |
+5.56% |
| 2013-03-31 | Rs546.30 Million ≈ $5.91 Million |
-5.21% |
| 2012-03-31 | Rs576.30 Million ≈ $6.23 Million |
+31.56% |
| 2011-03-31 | Rs438.04 Million ≈ $4.74 Million |
+22.81% |
| 2010-03-31 | Rs356.69 Million ≈ $3.86 Million |
-16.29% |
| 2009-03-31 | Rs426.09 Million ≈ $4.61 Million |
-22.84% |
| 2008-03-31 | Rs552.21 Million ≈ $5.97 Million |
-26.36% |
| 2007-03-31 | Rs749.83 Million ≈ $8.11 Million |
+5.14% |
| 2006-03-31 | Rs713.18 Million ≈ $7.71 Million |
-- |
About Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. … Read more